Literature DB >> 101456

Antigenicity of purified glutaraldehyde-treated cholera toxoid administered orally.

M M Levine, T P Hughes, C R Young, S O'Donnell, J P Craig, H P Holley, E J Bergquist.   

Abstract

The antigenicity of orally administered glutaraldehyde-treated cholera toxoid was investigated in healthy volunteers. Fourteen volunteers ingested two or three 2-mg doses of toxoid with saline, with the doses spaced at 28-day intervals. Thirteen other volunteers received comparable toxoid doses with NaHCO3 and milk to neutralize gastric acid. Increments in circulating antitoxin levels were used to assay the antigenicity of oral toxoid. Antitoxin was measured by adrenal cell, rabbit skin permeability factor, and passive hemagglutination assays in sera collected on days 0, 28, 35, 56, 63, and 84 after primary immunization. Adrenal cell and rabbit skin assays exhibited identical sensitivity in detecting antitoxin rises in the 27 vaccinees (19/27) and were significantly more sensitive than passive hemagglutination (11/27) (P less than 0.03). Volunteers who ingested toxoid with NaHCO3 and milk had a higher rate of seroconversion (77%) than those who received toxoid with saline (64%); they also had earlier rises in antitoxin titer and consistently higher geometric mean titers on all days tested. These studies demonstrate that purified cholera toxoid is antigenic in humans after oral administration. The possible role of oral toxoid in enhancing the protective effect of killed whole-cell vaccines can now be investigated.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 101456      PMCID: PMC421971          DOI: 10.1128/iai.21.1.158-162.1978

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  14 in total

1.  Immunity to experimental cholera. II. Secretory and humoral antitoxin response to local and systemic toxoid administration.

Authors:  N F Pierce; H Y Reynolds
Journal:  J Infect Dis       Date:  1975-04       Impact factor: 5.226

2.  Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid.

Authors:  A M Svennerholm; J Holmgren
Journal:  Infect Immun       Date:  1976-03       Impact factor: 3.441

3.  Neutralization of cholera enterotoxin-induced steroidogenesis by specific antibody.

Authors:  S T Donta
Journal:  J Infect Dis       Date:  1974-03       Impact factor: 5.226

4.  Shigellosis in custodial institutions. II. Clinical, immunologic and bacteriologic response of institutionalized children to oral attenuated shigella vaccines.

Authors:  M M Levine; H L Dupont; E J Gangarosa; R B Hornick; M J Snyder; J P Libonati; K Glaser; S B Formal
Journal:  Am J Epidemiol       Date:  1972-07       Impact factor: 4.897

5.  Immunity to experimental cholera. I. Protective effect of humoral IgG antitoxin demonstrated by passive immunization.

Authors:  N F Pierce; H Y Reynolds
Journal:  J Immunol       Date:  1974-09       Impact factor: 5.422

6.  Protection against enteric bacterial infection by secretory IgA antibodies.

Authors:  E S Fubara; R Freter
Journal:  J Immunol       Date:  1973-08       Impact factor: 5.422

7.  Cutaneous responses to cholera skin toxin in man. I. Responses in unimmunized American males.

Authors:  J P Craig; E R Eichner; R B Hornick
Journal:  J Infect Dis       Date:  1972-03       Impact factor: 5.226

8.  Development of a purified cholera toxoid. II. Preparation of a stable, antigenic toxoid by reaction of purified toxin with glutaraldehyde.

Authors:  R S Rappaport; G Bonde; T McCann; B A Rubin; H Tint
Journal:  Infect Immun       Date:  1974-02       Impact factor: 3.441

9.  Antitoxic immunity in experimental cholera: protection, and serum and local antibody responses in rabbits after enteral and parenteral immunization.

Authors:  J Holmgren; A M Svennerholm; O Ouchterlony; A Anderson; G Walletström; U Westerberg-Berndtsson
Journal:  Infect Immun       Date:  1975-12       Impact factor: 3.441

10.  Development of a purified cholera toxoid. I. Purification of toxin.

Authors:  R S Rappaport; B A Rubin; H Tint
Journal:  Infect Immun       Date:  1974-02       Impact factor: 3.441

View more
  8 in total

1.  Peroral immunization of rats with Escherichia coli heat-labile enterotoxin delivered by microspheres.

Authors:  F A Klipstein; R F Engert; W T Sherman
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

2.  Properties of cross-linked toxoid vaccines made with hyperantigenic forms of synthetic Escherichia coli heat-stable toxin.

Authors:  F A Klipstein; R F Engert; R A Houghten
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

3.  Immunity to enterotoxigenic Escherichia coli.

Authors:  M M Levine; D R Nalin; D L Hoover; E J Bergquist; R B Hornick; C R Young
Journal:  Infect Immun       Date:  1979-03       Impact factor: 3.441

4.  Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine.

Authors:  M M Levine; R E Black; M L Clements; C Lanata; S Sears; T Honda; C R Young; R A Finkelstein
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

5.  Microtiter enzyme-linked immunosorbent assay for immunoglobulin g cholera antitoxin in humans: sensitivity and specificity.

Authors:  R M Robins-Browne; C R Young; M M Levine; J P Craig
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

6.  Microtiter enzyme-linked immunosorbent assay for immunoglobulin G cholera antitoxin in humans: method and correlation with rabbit skin vascular permeability factor technique.

Authors:  C R Young; M M Levine; J P Craig; R Robins-Browne
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

7.  Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers.

Authors:  Zhiming Huo; Sara L Bissett; Raphaela Giemza; Simon Beddows; Clarissa Oeser; David J M Lewis
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

8.  Development of a vaccine against experimental cholera and Escherichia coli diarrheal disease.

Authors:  R S Rappaport; G Bonde
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.